EasySep™小鼠TIL（CD45）正选试剂盒
产品号 #72302_C
RHO/ROCK 信号通路抑制剂；抑制 ROCK1 和 ROCK2
若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系
总览
Y-27632是一种具有细胞通透性、效力强且选择性高的的ho 相关卷曲-螺旋结构蛋白激酶（ROCK）抑制剂。Y-27632 通过与 ATP 竞争结合催化位点来抑制 ROCK1 (Ki = 220 nM) 和 ROCK2 (Ki = 300 nM) (Davies 等；Ishizaki 等)。
维持与自我更新
·通过防止解离诱导的细胞凋亡（anoikis），提高人胚胎干细胞（ES）分离为单细胞后的存活率，从而提高其克隆效率（Watanabe等）。
·在强制聚集法中促进拟胚体的形成（Ungrin等）。
·提高冻存单细胞人 ES 细胞在复苏后的存活率（Li等）。
·小鼠 ES 细胞来源的神经前体细胞在解离及移植后的凋亡（Koyanagi等）。
重编程
·与 CHIR99021、RepSox、Forskolin、SP600125、Gö6983 和丙戊酸联合使用，将成纤维细胞直接谱系重编程为成熟神经元（Hu 等）。
分化
·在分化起始阶段提高人胚胎干细胞单层细胞的存活率（Rezania等）。
别名
ROCK i抑制剂
细胞类型
神经元，多能干细胞
种属
人，小鼠，非人灵长类，其它细胞系，大鼠
应用
分化，扩增，培养，重编程，球状体培养
研究领域
干细胞生物学
CAS 编号
129830-38-2
化学式
C₁₄H₂₁N₃O · 2HCl
分子量
320.3 克/摩尔
纯度
≥98%
通路
RHO/ROCK
靶点
ROCK1，ROCK2
产品说明书及文档
请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。
应用领域
本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。
相关材料与文献
技术资料 (5)
文献 (14)
Intrinsic Immunity Shapes Viral Resistance of Stem Cells. Cell 2018 JAN
Abstract
Stem cells are highly resistant to viral infection compared to their differentiated progeny; however, the mechanism is mysterious. Here, we analyzed gene expression in mammalian stem cells and cells at various stages of differentiation. We find that, conserved across species, stem cells express a subset of genes previously classified as interferon (IFN) stimulated genes (ISGs) but that expression is intrinsic, as stem cells are refractory to interferon. This intrinsic ISG expression varies in a cell-type-specific manner, and many ISGs decrease upon differentiation, at which time cells become IFN responsive, allowing induction of a broad spectrum of ISGs by IFN signaling. Importantly, we show that intrinsically expressed ISGs protect stem cells against viral infection. We demonstrate the in vivo importance of intrinsic ISG expression for protecting stem cells and their differentiation potential during viral infection. These findings have intriguing implications for understanding stem cell biology and the evolution of pathogen resistance.
A Novel Protocol for Directed Differentiation of C9orf72-Associated Human Induced Pluripotent Stem Cells Into Contractile Skeletal Myotubes STEM CELLS Translational Medicine 2016 NOV
Abstract
: Induced pluripotent stem cells (iPSCs) offer an unlimited resource of cells to be used for the study of underlying molecular biology of disease, therapeutic drug screening, and transplant-based regenerative medicine. However, methods for the directed differentiation of skeletal muscle for these purposes remain scarce and incomplete. Here, we present a novel, small molecule-based protocol for the generation of multinucleated skeletal myotubes using eight independent iPSC lines. Through combinatorial inhibition of phosphoinositide 3-kinase (PI3K) and glycogen synthase kinase 3β (GSK3β) with addition of bone morphogenic protein 4 (BMP4) and fibroblast growth factor 2 (FGF2), we report up to 64% conversion of iPSCs into the myogenic program by day 36 as indicated by MYOG+ cell populations. These cells began to exhibit spontaneous contractions as early as 34 days in vitro in the presence of a serum-free medium formulation. We used this protocol to obtain iPSC-derived muscle cells from frontotemporal dementia (FTD) patients harboring C9orf72 hexanucleotide repeat expansions (rGGGGCC), sporadic FTD, and unaffected controls. iPSCs derived from rGGGGCC carriers contained RNA foci but did not vary in differentiation efficiency when compared to unaffected controls nor display mislocalized TDP-43 after as many as 120 days in vitro. This study presents a rapid, efficient, and transgene-free method for generating multinucleated skeletal myotubes from iPSCs and a resource for further modeling the role of skeletal muscle in amyotrophic lateral sclerosis and other motor neuron diseases. SIGNIFICANCE Protocols to produce skeletal myotubes for disease modeling or therapy are scarce and incomplete. The present study efficiently generates functional skeletal myotubes from human induced pluripotent stem cells using a small molecule-based approach. Using this strategy, terminal myogenic induction of up to 64% in 36 days and spontaneously contractile myotubes within 34 days were achieved. Myotubes derived from patients carrying the C9orf72 repeat expansion show no change in differentiation efficiency and normal TDP-43 localization after as many as 120 days in vitro when compared to unaffected controls. This study provides an efficient, novel protocol for the generation of skeletal myotubes from human induced pluripotent stem cells that may serve as a valuable tool in drug discovery and modeling of musculoskeletal and neuromuscular diseases.
Efficient generation of functional CFTR-expressing airway epithelial cells from human pluripotent stem cells. Nature protocols 2015 MAR
Abstract
Airway epithelial cells are of great interest for research on lung development, regeneration and disease modeling. This protocol describes how to generate cystic fibrosis (CF) transmembrane conductance regulator protein (CFTR)-expressing airway epithelial cells from human pluripotent stem cells (PSCs). The stepwise approach from PSC culture to differentiation into progenitors and then mature epithelia with apical CFTR activity is outlined. Human PSCs that were inefficient at endoderm differentiation using our previous lung differentiation protocol were able to generate substantial lung progenitor cell populations. Augmented CFTR activity can be observed in all cultures as early as at 35 d of differentiation, and full maturation of the cells in air-liquid interface cultures occurs in textless5 weeks. This protocol can be used for drug discovery, tissue regeneration or disease modeling.
更多信息
| Molecular Weight | 320.3 g/mol |
|---|---|
| 种属 | Human, Mouse, Non-Human Primate, Other, Rat |
| Alternative Names | ROCK inhibitor |
| Cas Number | 129830-38-2 |
| Chemical Formula | C₁₄H₂₁N₃O · 2HCl |
| 纯度 | ≥ 98% |
| Target | ROCK1, ROCK2 |
| Pathway | RHO/ROCK |
相关产品
-
ReproRNA™-OKSGM一种非整合型、自我复制的 RNA 重编程载体，用于生成诱导多能干细胞
质量保证:
产品仅供研究使用，不用于针对人或动物的诊断或治疗。
产品仅供研究使用，不用于针对人或动物的诊断或治疗。
